SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 48.6% in July

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 18,400 shares, adeclineof48.6% from the July 15th total of 35,800 shares. Based on an average trading volume of 91,600 shares, the short-interest ratio is presently 0.2 days. Currently,0.0% of the company's shares are short sold. Currently,0.0% of the company's shares are short sold. Based on an average trading volume of 91,600 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently bought and sold shares of SOPH. Dimensional Fund Advisors LP increased its stake in SOPHiA GENETICS by 23.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock worth $68,000 after purchasing an additional 4,115 shares during the period. Silverberg Bernstein Capital Management LLC grew its position in shares of SOPHiA GENETICS by 54.4% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 34,675 shares of the company's stock worth $115,000 after buying an additional 12,211 shares in the last quarter. Ridgewood Investments LLC grew its position in shares of SOPHiA GENETICS by 1,930.5% during the first quarter. Ridgewood Investments LLC now owns 40,610 shares of the company's stock worth $135,000 after buying an additional 38,610 shares in the last quarter. Rathbones Group PLC acquired a new position in shares of SOPHiA GENETICS during the second quarter worth about $504,000. Finally, Federated Hermes Inc. grew its position in shares of SOPHiA GENETICS by 89.0% during the first quarter. Federated Hermes Inc. now owns 189,000 shares of the company's stock worth $627,000 after buying an additional 89,000 shares in the last quarter. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Trading Up 4.8%

Shares of NASDAQ SOPH traded up $0.1650 during trading on Friday, hitting $3.6050. 9,221 shares of the company were exchanged, compared to its average volume of 74,959. The firm has a market capitalization of $243.63 million, a PE ratio of -8.13 and a beta of 1.00. SOPHiA GENETICS has a 12-month low of $2.58 and a 12-month high of $4.92. The company has a fifty day moving average price of $3.29 and a 200-day moving average price of $3.24. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.21 and a current ratio of 3.39.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.58. The firm had revenue of $18.32 million for the quarter, compared to analyst estimates of $17.49 million. SOPHiA GENETICS had a negative net margin of 40.99% and a negative return on equity of 30.69%. SOPHiA GENETICS has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that SOPHiA GENETICS will post -0.96 EPS for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.